| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
3 companies
Shanafelt Armen is a Director at Rein Therapeutics, Inc. with holdings across 3 companies. Recent SEC Form 4 filings include 5 buys and 0 sells.
Estimated insider holdings value: $108.8M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 13, 2021 | SYRE Spyre Therapeutics, Inc. | Director | Buy | 150,000 | $3.66 | $549,692.38 | +58.3% | -49.9% | -89.7% | |
| Jul 5, 2017 | RNTX Rein Therapeutics, Inc. | Director | Buy | 250,000 | $15.00 | $3,750,000.00 | +29.6% | - | - | |
| Aug 16, 2016 | PTGX Protagonist Therapeutics, Inc | Director, 10% Owner | Buy | 583,333 | $12.00 | $6,999,996.00 | +38.5% | - | - |